Comprehensive genomic profiling of metastatic tumors in a phase II biomarker study of everolimus in advanced renal cell carcinoma

PURPOSE: Genomic events leading to activation of mechanistic target of rapamycin (mTOR) are common in renal cell carcinoma (RCC). Everolimus is an allosteric mTOR inhibitor with efficacy in metastatic RCC (mRCC). We characterized the genomic profile of RCC tumors from metastatic sites and assessed w...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Genitourin Cancer
Asıl Yazarlar: Gao, Xin, Jegede, Opeyemi, Gray, Connor, Catalano, Paul J., Novak, Jesse, Kwiatkowski, David J., McKay, Rana R., George, Daniel J., Choueiri, Toni K., McDermott, David F., Signoretti, Sabina, Bhatt, Rupal S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6175670/
https://ncbi.nlm.nih.gov/pubmed/29754934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.04.001
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller